Search - tctmd.com

Displaying 261 - 280 of 412

Sort: Relevancy | Date

Presentation ACC 2022

Updated Cumulative Results Of Treatment With Mavacamten From The EXPLORER-LTE Cohort Of The MAVA-LTE Study In Patients With Obstructive Hypertrophic Cardiomyopathy

Presenter: Florian Rader

April 04, 2022

Presentation ACC 2022

The Effect Of Omecamtiv Mecarbil On Exercise Tolerance In Patients With Chronic Heart Failure And Reduced Ejection Fraction: METEORIC-HF

Presenter: Michael Felker

April 04, 2022

Presentation ACC 2022

A Cluster-Randomized PRagmatic Trial Aimed At ImprOving Use Of Guideline Directed Medical Therapy In OutPatienTs With Heart Failure: PROMPT-HF

Presenter: Tariq Ahmad

April 04, 2022

News Conference News ACC 2022

PROMPT-HF: Pop-up Alerts Improve HFrEF Medication Optimization

L.A. McKeown

April 03, 2022

News Conference News ACC 2022

Mavacamten Yields Stable Benefits in Obstructive HCM Over Longer Term

Shelley Wood

April 03, 2022

News Conference News ACC 2022

New HF Guidelines Stress Four-Drug Approach, ‘HFmrEF,’ Amyloidosis Options, and More

Shelley Wood

April 01, 2022

News Daily News

Empagliflozin Plus an MRA Is Safe in HFpEF, May Help With Hyperkalemia

L.A. McKeown

March 22, 2022

News Daily News

Guideline-Directed Therapies Underused in Frail HF Patients

L.A. McKeown

March 11, 2022

News Daily News

FDA Approves Empagliflozin for Treatment of HFpEF

Michael O'Riordan

February 24, 2022

News Conference News THT 2022

Probe Beyond Ejection Fraction to Understand and Manage HFpEF

L.A. McKeown

February 07, 2022

News Conference News STS 2022

Tricuspid Repair During Mitral Valve Surgery Prevents TR Progression

Michael O'Riordan

February 04, 2022

News Conference News STS 2022

Modified Surgical MV Repair Stands Up to Replacement

Michael O'Riordan

February 03, 2022

News Daily News

In the US, HF Prevalence—and Costs—Rising Steeply: HFSA Report

Michael O'Riordan

January 27, 2022

News Daily News

Journal of Cardiac Failure Launches Rapid Publication Platform to Spark Discourse

Todd Neale

January 21, 2022

News Daily News

Meta-analysis of Pivotal SGLT2 Inhibitor Trials Boosts Hopes in HFpEF

L.A. McKeown

December 07, 2021

Presentation Controversies and Advances 2021

SGLT2 Inhibitors and Heart Failure

Presenter: Michelle M. Kittleson

December 03, 2021

Presentation Controversies and Advances 2021

Role of Digoxin in Heart Failure and Atrial Fibrillation

Presenter: Michelle M. Kittleson

December 03, 2021

Presentation Controversies and Advances 2021

In Defense of Digoxin

Presenter: John Mandrola

December 03, 2021

News Opinion CV Team Dispatch

December 2021 News Roundup

L.A. McKeown

December 01, 2021

News Conference News AHA 2021

Risk-Based EHR Alert Doesn’t Improve HF Care or Outcomes: REVEAL-HF

Michael O'Riordan

November 19, 2021

Advertisement

Updated Cumulative Results Of Treatment With Mavacamten From The EXPLORER-LTE Cohort Of The MAVA-LTE Study In Patients With Obstructive Hypertrophic Cardiomyopathy

The Effect Of Omecamtiv Mecarbil On Exercise Tolerance In Patients With Chronic Heart Failure And Reduced Ejection Fraction: METEORIC-HF

A Cluster-Randomized PRagmatic Trial Aimed At ImprOving Use Of Guideline Directed Medical Therapy In OutPatienTs With Heart Failure: PROMPT-HF

PROMPT-HF: Pop-up Alerts Improve HFrEF Medication Optimization

Mavacamten Yields Stable Benefits in Obstructive HCM Over Longer Term

New HF Guidelines Stress Four-Drug Approach, ‘HFmrEF,’ Amyloidosis Options, and More

Empagliflozin Plus an MRA Is Safe in HFpEF, May Help With Hyperkalemia

Guideline-Directed Therapies Underused in Frail HF Patients

FDA Approves Empagliflozin for Treatment of HFpEF

Probe Beyond Ejection Fraction to Understand and Manage HFpEF

Tricuspid Repair During Mitral Valve Surgery Prevents TR Progression

Modified Surgical MV Repair Stands Up to Replacement

In the US, HF Prevalence—and Costs—Rising Steeply: HFSA Report

Journal of Cardiac Failure Launches Rapid Publication Platform to Spark Discourse

Meta-analysis of Pivotal SGLT2 Inhibitor Trials Boosts Hopes in HFpEF

SGLT2 Inhibitors and Heart Failure

Role of Digoxin in Heart Failure and Atrial Fibrillation

In Defense of Digoxin

December 2021 News Roundup

Risk-Based EHR Alert Doesn’t Improve HF Care or Outcomes: REVEAL-HF

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content